Kintai’s obesity drug that works via the gut microbiome moves closer to the clinic

Kintai’s obesity drug that works via the gut microbiome moves closer to the clinic

Source: 
Fierce Biotech
snippet: 

Microbes that live in the gut are believed to play an important role in human metabolism. Kintai Therapeutics, a Flagship Pioneering portfolio company, says its drug candidate that leverages the microbiome showed sustained weight loss, as well as markers of improved glucose control and liver health in rodents.